speb/financial-data huggingface dataset:
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 19578720000.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 18638760000.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 18638760000.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 12685810000.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 12685810000.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 28300000.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 28300000.00
MEDPLUS.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 38830000.00
MEDPLUS.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 38830000.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 51261.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 51261.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Work In Process: 6130000.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 6130000.00
MEDPLUS.NS balance_sheet (annual, 2026-03-31) — Working Capital: 13793590000.00
MEDPLUS.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 13793590000.00
MEDPLUS.NS income_statement (annual, 2026-03-31) — Write Off: 3150000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — +Operating Expense: 4049900000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — +Total Revenue: 18796000000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Basic Average Shares: 120202899.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Basic EPS: 2.76
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Cost Of Revenue: 14192890000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Depreciation And Amortization In Income Statement: 779210000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Depreciation Income Statement: 779210000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Diluted Average Shares: 120202899.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Diluted EPS: 2.76
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Diluted NI Availto Com Stockholders: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — EBIT: 751470000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — EBITDA: 1530680000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Gross Profit: 4603110000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Interest Expense: 332700000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Interest Expense Non Operating: 332700000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Minority Interests: 90000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income Common Stockholders: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income Continuous Operations: 331670000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income From Continuing And Discontinued Operation: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income From Continuing Operation Net Minority Interest: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Income Including Noncontrolling Interests: 331670000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Interest Income: -332700000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Net Non Operating Interest Income Expense: -332700000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Normalized EBITDA: 1530680000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Normalized Income: 331760000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Operating Income: 553210000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Operating Revenue: 18796000000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Other Non Operating Income Expenses: 198260000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Other Operating Expenses: 851630000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Otherunder Preferred Stock Dividend: 0.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Pretax Income: 418770000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Reconciled Cost Of Revenue: 14192890000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Reconciled Depreciation: 779210000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Tax Effect Of Unusual Items: 0.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Tax Provision: 87100000.00
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Tax Rate For Calcs: 0.21
MEDPLUS.NS income_statement (quarterly, 2026-06-30) — Total Expenses: 18242790000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Cash Equivalents: 800000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Cash Financial: 209100000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Common Stock Dividend Paid: -41300000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Common Stock Issuance: 294700000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 294700000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 265200000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -255100000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: 31200000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: 10100000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Net Other Financing Charges: 100000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -100000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Non Current Deferred Assets: 6900000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Other Current Assets: -200000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Other Non Current Liabilities: 100000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Other Short Term Investments: 200000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Purchase Of Investment: -200000.00
MEDX.SW cash_flow (annual, 2021-12-31) — Sale Of Intangibles: 0.00
MEDX.SW cash_flow (annual, 2021-12-31) — Sale Of Investment: 31400000.00
MEDX.SW balance_sheet (annual, 2021-12-31) — Tradeand Other Payables Non Current: 1700000.00
MEDX.SW income_statement (annual, 2021-12-31) — Write Off: 0.00
MEDX.SW income_statement (annual, 2022-12-31) — +Operating Expense: 125900000.00
MEDX.SW income_statement (annual, 2022-12-31) — +Total Revenue: 477100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Accounts Payable: 47400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Accounts Receivable: 59600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -162600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -2300000.00
MEDX.SW income_statement (annual, 2022-12-31) — Basic Average Shares: 40957744.00
MEDX.SW income_statement (annual, 2022-12-31) — Basic EPS: 0.28
MEDX.SW cash_flow (annual, 2022-12-31) — Beginning Cash Position: 209800000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 53500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Capital Expenditure: -38600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 71500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Capital Stock: 400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 313500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 316800000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -15000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Cash Equivalents: 208100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Cash Financial: 105400000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Inventory: -30500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 17400000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Payable: 10000000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 1300000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Receivables: -38900000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Change In Working Capital: -47600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Changes In Cash: 106700000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Common Stock: 400000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -15000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Common Stock Equity: 504800000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Common Stock Payments: -6100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Construction In Progress: 31000000.00
MEDX.SW income_statement (annual, 2022-12-31) — Cost Of Revenue: 301700000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Assets: 489000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 9000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Debt: 155100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 164100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Liabilities: 271100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Current Provisions: 4200000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Deferred Tax: 600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Defined Pension Benefit: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Depreciation: 51100000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 51100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 0.00
MEDX.SW income_statement (annual, 2022-12-31) — Diluted Average Shares: 41100022.00
MEDX.SW income_statement (annual, 2022-12-31) — Diluted EPS: 0.28
MEDX.SW income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 11600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Dividends Payable: 5500000.00
MEDX.SW income_statement (annual, 2022-12-31) — EBIT: 18600000.00
MEDX.SW income_statement (annual, 2022-12-31) — EBITDA: 69700000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -2900000.00
MEDX.SW cash_flow (annual, 2022-12-31) — End Cash Position: 313500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Financing Cash Flow: 116100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Finished Goods: 41400000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Free Cash Flow: 9000000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 0.00
MEDX.SW income_statement (annual, 2022-12-31) — General And Administrative Expense: 103000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Goodwill: 254400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 374900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 61900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Gross PPE: 392400000.00
MEDX.SW income_statement (annual, 2022-12-31) — Gross Profit: 175400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Hedging Assets Current: 2300000.00
MEDX.SW income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 1500000.00
MEDX.SW income_statement (annual, 2022-12-31) — Interest Expense: 6400000.00
MEDX.SW income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 6400000.00
MEDX.SW income_statement (annual, 2022-12-31) — Interest Income: 700000.00
MEDX.SW income_statement (annual, 2022-12-31) — Interest Income Non Operating: 700000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Interest Paid Cfo: -6500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Interest Received Cfo: 600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Inventory: 91800000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Invested Capital: 906800000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Investing Cash Flow: -57000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 6500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Investmentsin Associatesat Cost: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Issuance Of Debt: 310500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Land And Improvements: 68000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 62500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Long Term Debt: 246900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 309400000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -3000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 0.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Long Term Provisions: 200000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 203600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Minority Interest: 0.00
MEDX.SW income_statement (annual, 2022-12-31) — Minority Interests: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -16700000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -6100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Net Debt: 88500000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 11600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 11600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -2200000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Interest Income: -5600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -3000000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 145900000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -3000000.00
MEDX.SW income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -5600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 200000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Net PPE: 229800000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -35100000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 148900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 129900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 5800000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 16100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 4400000.00
MEDX.SW income_statement (annual, 2022-12-31) — Normalized EBITDA: 93500000.00
MEDX.SW income_statement (annual, 2022-12-31) — Normalized Income: 34186200.00
MEDX.SW cash_flow (annual, 2022-12-31) — Operating Cash Flow: 47600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Operating Income: 49500000.00
MEDX.SW income_statement (annual, 2022-12-31) — Operating Revenue: 477100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 40914834.00
MEDX.SW cash_flow (annual, 2022-12-31) — Other Cash Adjustment Outside Changein Cash: -100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 1600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 120500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Other Non Cash Items: 48300000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Non Current Assets: -100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: -100000.00
MEDX.SW income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Properties: 36300000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Receivables: 2400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 3300000.00
MEDX.SW income_statement (annual, 2022-12-31) — Other Special Charges: 15400000.00
MEDX.SW income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Payables: 59200000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 4500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Prepaid Assets: 11600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Pretax Income: 12200000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Properties: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Purchase Of Business: -16700000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -2200000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Purchase Of Investment: -3300000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Purchase Of PPE: -36400000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Raw Materials: 26800000.00
MEDX.SW income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 301700000.00
MEDX.SW income_statement (annual, 2022-12-31) — Reconciled Depreciation: 51100000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Repayment Of Debt: -164600000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -6100000.00
MEDX.SW income_statement (annual, 2022-12-31) — Research And Development: 23600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 1600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Retained Earnings: 540300000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Sale Of Business: 0.00
MEDX.SW cash_flow (annual, 2022-12-31) — Sale Of Investment: 300000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Sale Of PPE: 1300000.00
MEDX.SW income_statement (annual, 2022-12-31) — Selling General And Administration: 103000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Share Issued: 41262370.00
MEDX.SW cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 310500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Short Term Debt Payments: -161600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Special Income Charges: -27000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Stockholders Equity: 504800000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Tangible Book Value: 129900000.00
MEDX.SW income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -1213800.00
MEDX.SW income_statement (annual, 2022-12-31) — Tax Provision: 600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.05
MEDX.SW balance_sheet (annual, 2022-12-31) — Taxes Receivable: 4500000.00
MEDX.SW cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -10500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Assets: 1105900000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Capitalization: 751700000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Debt: 473500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 504800000.00
MEDX.SW income_statement (annual, 2022-12-31) — Total Expenses: 427600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 601100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 617000000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 330000000.00
MEDX.SW income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 19600000.00
MEDX.SW income_statement (annual, 2022-12-31) — Total Other Finance Cost: -100000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Total Tax Payable: 6300000.00
MEDX.SW income_statement (annual, 2022-12-31) — Total Unusual Items: -23800000.00
MEDX.SW income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -23800000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 347536.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Treasury Stock: 12500000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Work In Process: 23600000.00
MEDX.SW balance_sheet (annual, 2022-12-31) — Working Capital: 217900000.00
MEDX.SW income_statement (annual, 2022-12-31) — Write Off: 8500000.00
MEDX.SW income_statement (annual, 2023-12-31) — +Operating Expense: 143400000.00
MEDX.SW income_statement (annual, 2023-12-31) — +Total Revenue: 486600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Accounts Payable: 49400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Accounts Receivable: 56800000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -173400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -1300000.00
MEDX.SW income_statement (annual, 2023-12-31) — Basic Average Shares: 40868426.00
MEDX.SW income_statement (annual, 2023-12-31) — Basic EPS: 0.01
MEDX.SW cash_flow (annual, 2023-12-31) — Beginning Cash Position: 313500000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 53000000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Capital Expenditure: -52900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 70900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Capital Stock: 400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 112100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 112100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -15000000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Cash Equivalents: 3100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Cash Financial: 127500000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Inventory: 1200000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -6500000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Payable: -3300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -800000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Receivables: 2000000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Change In Working Capital: -1800000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Changes In Cash: -178300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Common Stock: 400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Common Stock Equity: 465400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Common Stock Payments: -3100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Construction In Progress: 39800000.00
MEDX.SW income_statement (annual, 2023-12-31) — Cost Of Revenue: 328900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Assets: 308100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 10700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Debt: 31500000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 42200000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Liabilities: 178100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Current Provisions: 18300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Deferred Tax: 2200000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Defined Pension Benefit: 22100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Depreciation: 58400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 58400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Derivative Product Liabilities: 12000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Diluted Average Shares: 41203685.00
MEDX.SW income_statement (annual, 2023-12-31) — Diluted EPS: 0.01
MEDX.SW income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Dividends Payable: 10900000.00
MEDX.SW income_statement (annual, 2023-12-31) — EBIT: 13000000.00
MEDX.SW income_statement (annual, 2023-12-31) — EBITDA: 71400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -4600000.00
MEDX.SW cash_flow (annual, 2023-12-31) — End Cash Position: 130600000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Financing Cash Flow: -153800000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Finished Goods: 42900000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Free Cash Flow: 3200000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 0.00
MEDX.SW income_statement (annual, 2023-12-31) — General And Administrative Expense: 119000000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Goodwill: 268500000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 396000000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 58100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Gross PPE: 431500000.00
MEDX.SW income_statement (annual, 2023-12-31) — Gross Profit: 157600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 4800000.00
MEDX.SW income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 3000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Interest Expense: 10100000.00
MEDX.SW income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 10100000.00
MEDX.SW income_statement (annual, 2023-12-31) — Interest Income: 1400000.00
MEDX.SW income_statement (annual, 2023-12-31) — Interest Income Non Operating: 1400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Interest Paid Cfo: -6300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Interest Received Cfo: 1300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Inventory: 88400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Invested Capital: 744200000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Investing Cash Flow: -80600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 7700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Investmentsin Associatesat Cost: 5700000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Issuance Of Debt: 33600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Land And Improvements: 69800000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 60200000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Long Term Debt: 247300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 307500000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 5700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Long Term Provisions: 2700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 229100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Minority Interest: 9000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Minority Interests: -400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -31100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -3100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Net Debt: 166700000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income: 300000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 300000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 700000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 300000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 700000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 700000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -6500000.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Interest Income: -9900000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 3300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -123600000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 0.00
MEDX.SW income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -9900000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Net PPE: 258100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -46200000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: -123600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 69400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 8700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 19400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1500000.00
MEDX.SW income_statement (annual, 2023-12-31) — Normalized EBITDA: 69700000.00
MEDX.SW income_statement (annual, 2023-12-31) — Normalized Income: -1255500.00
MEDX.SW cash_flow (annual, 2023-12-31) — Operating Cash Flow: 56100000.00
MEDX.SW income_statement (annual, 2023-12-31) — Operating Income: 14200000.00
MEDX.SW income_statement (annual, 2023-12-31) — Operating Revenue: 486600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 40781847.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Current Assets: 6300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 2500000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 127500000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Other Non Cash Items: 9400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 11200000.00
MEDX.SW income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Payable: 8100000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Properties: 39800000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Other Receivables: 2000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Other Special Charges: -2000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Payables: 83000000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 2500000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Prepaid Assets: 10100000.00
MEDX.SW income_statement (annual, 2023-12-31) — Pretax Income: 2900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Properties: 0.00
MEDX.SW cash_flow (annual, 2023-12-31) — Purchase Of Business: -35100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -6500000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
MEDX.SW cash_flow (annual, 2023-12-31) — Purchase Of PPE: -46400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Raw Materials: 21900000.00
MEDX.SW income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 328900000.00
MEDX.SW income_statement (annual, 2023-12-31) — Reconciled Depreciation: 58400000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Repayment Of Debt: -157200000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -3100000.00
MEDX.SW income_statement (annual, 2023-12-31) — Research And Development: 25700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Restricted Cash: 18500000.00
MEDX.SW income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Retained Earnings: 529800000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Sale Of Business: 4000000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Sale Of Investment: 3300000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Sale Of PPE: 200000.00
MEDX.SW income_statement (annual, 2023-12-31) — Selling General And Administration: 119000000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Share Issued: 41262370.00
MEDX.SW cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 33600000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -157200000.00
MEDX.SW income_statement (annual, 2023-12-31) — Special Income Charges: 300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Stockholders Equity: 465400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Tangible Book Value: 69400000.00
MEDX.SW income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 144500.00
MEDX.SW income_statement (annual, 2023-12-31) — Tax Provision: 2200000.00
MEDX.SW income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.09
MEDX.SW balance_sheet (annual, 2023-12-31) — Taxes Receivable: 9100000.00
MEDX.SW cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -7900000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Assets: 1006800000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Capitalization: 712700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Debt: 349700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 474400000.00
MEDX.SW income_statement (annual, 2023-12-31) — Total Expenses: 472300000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 532400000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 698700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 354300000.00
MEDX.SW income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 16000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Total Other Finance Cost: 1200000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Total Tax Payable: 14600000.00
MEDX.SW income_statement (annual, 2023-12-31) — Total Unusual Items: 1700000.00
MEDX.SW income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 1700000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 480523.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Treasury Stock: 15200000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Work In Process: 23600000.00
MEDX.SW balance_sheet (annual, 2023-12-31) — Working Capital: 130000000.00
MEDX.SW income_statement (annual, 2023-12-31) — Write Off: -2200000.00
MEDX.SW income_statement (annual, 2024-12-31) — +Operating Expense: 141600000.00
MEDX.SW income_statement (annual, 2024-12-31) — +Total Revenue: 483900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Accounts Payable: 39400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 39400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Accounts Receivable: 43800000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 43800000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -190900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -190900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -600000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -600000.00
MEDX.SW income_statement (annual, 2024-12-31) — Basic Average Shares: 40779842.00
MEDX.SW income_statement (annual, 2024-12-31) — Basic EPS: -0.18
MEDX.SW cash_flow (annual, 2024-12-31) — Beginning Cash Position: 130600000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 47200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 47200000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Capital Expenditure: -48500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 65000000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 65000000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Capital Stock: 400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Capital Stock: 400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 96200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 96200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 96200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 96200000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -15000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Inventory: 14900000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 10600000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Payable: -7200000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 2900000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Receivables: 12400000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Change In Working Capital: 35000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Changes In Cash: -13500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Common Stock: 400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Common Stock: 400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Common Stock Equity: 436400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 436400000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Common Stock Payments: -500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Construction In Progress: 33800000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 33800000.00
MEDX.SW income_statement (annual, 2024-12-31) — Cost Of Revenue: 324200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Assets: 261200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Assets: 261200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 10700000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 10700000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Debt: 10200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Debt: 10200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 20900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 20900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Liabilities: 162900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 162900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Current Provisions: 17300000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Current Provisions: 17300000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Deferred Tax: 0.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Defined Pension Benefit: 18700000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Defined Pension Benefit: 18700000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Depreciation: 61600000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 61600000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 20600000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Derivative Product Liabilities: 20600000.00
MEDX.SW income_statement (annual, 2024-12-31) — Diluted Average Shares: 41410284.00
MEDX.SW income_statement (annual, 2024-12-31) — Diluted EPS: -0.18
MEDX.SW income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -7400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Dividends Payable: 16300000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Dividends Payable: 16300000.00
MEDX.SW income_statement (annual, 2024-12-31) — EBIT: 5700000.00
MEDX.SW income_statement (annual, 2024-12-31) — EBITDA: 67300000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 1000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — End Cash Position: 118100000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Financing Cash Flow: -48600000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Finished Goods: 34800000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Finished Goods: 34800000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Free Cash Flow: 38100000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: -800000.00
MEDX.SW income_statement (annual, 2024-12-31) — General And Administrative Expense: 116400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Goodwill: 271600000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Goodwill: 271600000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 388800000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Goodwill And Other Intangible Assets: 388800000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 44400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Gross Accounts Receivable: 44400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Gross PPE: 452900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Gross PPE: 452900000.00
MEDX.SW income_statement (annual, 2024-12-31) — Gross Profit: 159700000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 1000000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Hedging Assets Current: 1000000.00
MEDX.SW income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 5200000.00
MEDX.SW income_statement (annual, 2024-12-31) — Interest Expense: 12000000.00
MEDX.SW income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 12000000.00
MEDX.SW income_statement (annual, 2024-12-31) — Interest Income: 1100000.00
MEDX.SW income_statement (annual, 2024-12-31) — Interest Income Non Operating: 1100000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Interest Paid Cfo: -12700000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Interest Received Cfo: 800000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Inventory: 75400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Inventory: 75400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Invested Capital: 694800000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Invested Capital: 694800000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Investing Cash Flow: -51500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 8000000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Investmentin Financial Assets: 8000000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Investmentsin Associatesat Cost: 0.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Investmentsin Associatesat Cost: 0.00
MEDX.SW cash_flow (annual, 2024-12-31) — Issuance Of Debt: 16400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Land And Improvements: 85900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 85900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 54300000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 54300000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Long Term Debt: 248200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Long Term Debt: 248200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 302500000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 302500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 0.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Long Term Equity Investment: 0.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Long Term Provisions: 2900000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Long Term Provisions: 2900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 243200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 243200000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Minority Interest: 10300000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Minority Interest: 10300000.00
MEDX.SW income_statement (annual, 2024-12-31) — Minority Interests: -1000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -4500000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Net Debt: 162200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Net Debt: 162200000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: -3700000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income: -7400000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -7400000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -6300000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -7400000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -7400000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -6400000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -6300000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -10000000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Interest Income: -11700000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 0.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -21300000.00
MEDX.SW income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -11700000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 100000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Net PPE: 262000000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Net PPE: 262000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -37000000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: -21300000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 47600000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 47600000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 15400000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Taxes Assets: 15400000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 16500000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Taxes Liabilities: 16500000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 2100000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 2100000.00
MEDX.SW income_statement (annual, 2024-12-31) — Normalized EBITDA: 78200000.00
MEDX.SW income_statement (annual, 2024-12-31) — Normalized Income: 3423700.00
MEDX.SW cash_flow (annual, 2024-12-31) — Operating Cash Flow: 86600000.00
MEDX.SW income_statement (annual, 2024-12-31) — Operating Income: 18100000.00
MEDX.SW income_statement (annual, 2024-12-31) — Operating Revenue: 483900000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 40790752.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 40790752.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Other Current Assets: 7000000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Other Current Assets: 7000000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 13700000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 13700000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 117200000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Other Intangible Assets: 117200000.00
MEDX.SW cash_flow (annual, 2024-12-31) — Other Non Cash Items: 12300000.00
MEDX.SW balance_sheet (annual, 2024-12-31) — Other Non Current Assets: -100000.00
MEDX.SW balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: -100000.00
MEDX.SW income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 600000.00
MEDX.SW income_statement (annual, 2024-12-31) — Other Operating Expenses: 100000.00